Leveraging advancements in gene therapies and a deep understanding of the molecular pathways involved in neurodegenerative diseases, Celosia Therapeutics is at the forefront of developing innovative solutions for these conditions. As a privately held pre-clinical stage company, they focus on addressing the therapeutic gaps in neurodegenerative diseases that currently have limited treatment options available. By utilizing gene therapy, Celosia Therapeutics aims to provide new hope and improved outcomes for patients suffering from these debilitating conditions.